About Us
We are advancing potential
therapies to improve the
futures of people living
with devastating
neuromuscular and
neurological diseases
A clinical stage biotech company, PepGen is advancing a new generation of oligonucleotide therapies capable, for the first time, of potentially transforming clinical outcomes for individuals with neuromuscular and neurological diseases.
We are leveraging our Enhanced Delivery Oligonucleotide (EDO) platform to solve the delivery challenges associated with previous generations of therapies and, achieve deep tissue penetration and high uptake to key muscle tissues.
We have a bold goal, and we won’t stop until we reach it
We are committed to developing truly transformative therapies resulting in clinically meaningful outcomes for individuals living with neuromuscular and neurological diseases including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), and ultimately, will expand into additional indications.
Team
Together we can solve the most difficult challenges and create a new future
We are scientists, physicians, advocates and biotech industry leaders. We bring expertise across scientific, medical, and business disciplines.
But our superpower is our commitment to changing the future.
Executive Team
Senior Leadership
Board Of Directors
Scientific Advisors
-
JOHN W. DAY, MD, PHD
Professor of Neurology, Pediatrics (Genetics) and Pathology, Stanford University
LEARN MORE
